What question did this study set out to answer?

To determine whether exposure to glitazones, DPP4 inhibitors, or GLP-1 receptor agonists is associated with an altered risk of Parkinson's disease compared to other oral glucose-lowering drugs in patients with diabetes.

July 17, 2020BrainOpen Access

Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes

View Full Paper

Ask AI

Bookmark

Authors

RBRuth BrauerUniversity of London LWLi WeiUniversity of London TMTiantian MaQinghai University

Discussion

Member takes

Implication

Cohort study reveals lower Parkinson's disease incidence with incretin therapies in adults with diabetes, suggesting potential neuroprotective benefits of these drugs.

Key Points

To determine whether exposure to glitazones, DPP4 inhibitors, or GLP-1 receptor agonists is associated with an altered risk of Parkinson's disease compared to other oral glucose-lowering drugs in patients with diabetes.
Conducted a population-based, longitudinal cohort study using primary care data from The Health Improvement Network (January 2006 to January 2019) in 100,288 patients with diabetes.
Identified incident Parkinson's disease over a median follow-up of 3.33 years.
Compared drug exposures using Cox proportional hazards regression with inverse probability of treatment weighting based on propensity scores.
DPP4 inhibitor use and GLP-1 mimetic use were associated with significantly lower rates of Parkinson's disease compared to the control group (5 and 4 vs. 10 per 10,000 person-years; IRR 0.64, 95% CI 0.43–0.88, P < 0.01 and IRR 0.38, 95% CI 0.17–0.60, P < 0.01, respectively).
Glitazone use showed no significant association with Parkinson's disease incidence compared to other oral antidiabetic agents (8 vs. 10 per 10,000 person-years; IRR 1.17, 95% CI 0.76–1.63, P = 0.467).

Cite This Study

Brauer et al. (2020) studied this question.

synapsesocial.com/papers/6a7dc1c4e5379bb2b27d8b54 https://doi.org/10.1093/brain/awaa262

View Full Paper

Ask AI

Bookmark

Implication

Cohort study reveals lower Parkinson's disease incidence with incretin therapies in adults with diabetes, suggesting potential neuroprotective benefits of these drugs.

Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes

Discussion

Member takes

Implication

Key Points

Cite This Study

Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider